Senvelgo®: SGLT-2 inhibition in the nephron
- Highly selective: targets SGLT-2 with only minor effect on SGLT-1
- Inhibits most reabsorption of glucose
- Promotes excretion of excess glucose in the urine
- Controls hyperglycaemia by bringing blood glucose into the target range1,2
- Reduces glucose toxicity
- Controls clinical signs of feline diabetes
- Minor inhibition of SGLT-1 allows reabsorption of sufficient glucose, preventing symptomatic hypoglycaemia
“This is the development in diabetes management we have been waiting many years for; a practical oral therapy to treat this challenging disease.”
Samantha Taylor
BVetMed(Hons) CertSAM DipECVIM-CA MANZCVS FRCVS
RCVS Recognised Specialist in Feline Medicine
Glycaemic control can be achieved within a week1,2
Blood glucose is usually brought into the target range within 7 days of starting Senvelgo®:1,2
- 60-day field study
- Included both newly diagnosed and insulin pretreated cats
- Randomised to receive once daily Senvelgo® or twice daily insulin
- Clinical control and quality of life improved in both groups
Sustained Efficacy
Serum fructosamine was controlled for the full study duration in a large field trial:10
- 6 month field study
- 252 owned diabetic cats
- 214 newly diagnosed and 38 insulin pretreated cats
Tested extensively, proven repeatedly1,10,11
Senvelgo® delivers glycaemic control and peace of mind
-
Efficacy and safety evaluated in studies featuring over 300 insulin-naive and insulin-treated cats 1,10,11
-
Senvelgo® is brought to you by the makers of ProZinc®, a proven and trusted insulin solution for diabetic pets
-
Senvelgo® is supported by Boehringer Ingelheim Animal Health’s technical services team, which is highly experienced in diabetes management
-
Cats that received Senvelgo® during studies experienced no episodes of symptomatic hypoglycaemia
By just day 30:
67% of owners reported very good or excellent quality of life in their cats12
87% cats reported as having good, very good or excellent overall diabetic control by their vets12
-
1. Niessen, S. J. M. et al. (2022) Once daily oral therapy for feline diabetes mellitus: evaluation of SGLT-2 inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats. Journal of Veterinary Internal Medicine 36, 2512–2513.
-
2. Sparkes, A. H. et al. (2015) ISFM Consensus Guidelines on the Practical Management of Diabetes Mellitus in Cats. J Feline Med Surg 17, 235–50.
-
3. McCann, T., et al. (2007) Feline diabetes mellitus in the UK: the prevalence within an insured cat population and a questionnaire-based putative risk factor analysis. J Feline Med Surg 9, 289–9.
-
4. O’Neill, D., et al. (2016) Epidemiology of Diabetes Mellitus among 193,435 Cats Attending Primary-Care Veterinary Practices in England. J Vet Intern Med 30, 964–72.
-
5. Rand J, Gottlieb, SA. Feline diabetes mellitus. Textbook of Veterinary Internal Medicine, 8th edition. Ettinger SJ, Feldman EC and Cote E, eds. Elsevier, Missouri. 2017;1781-1795.
-
6. 2018 Summary of the Veterinary Clinic: Pet Obesity Prevalence Survey & Pet Owner: Weight Management, Nutrition, and Pet Food Survey. Available at:
https://petobesityprevention.org/2018. -
7. Niessen, S. J. M. et al. (2017) The Big Pet Diabetes Survey: Perceived Frequency and Triggers for Euthanasia. Vet Sci 4, 27.
-
8. Diabetes in Cats: Quantitative market research study. Proprietary presentation, July 19, 2021. Kynetec; St. Louis, MO, on behalf of Boehringer Ingelheim.
-
9. Niessen, S. J. M. et al. (2010) Evaluation of a quaility-of-life tool for cats with diabetes mellitus. J Vet Intern Med 24, 1098-105.
-
10. Behrend, E. N. et al. (2023) Velagliflozin, an SGLT2 Inhibitor, as a once-daily, oral solution, stand-alone therapy for feline diabetes mellitus. Oral abstract presentation, 2023 ACVIM Forum, Pennsylvania, Jun 15-17.
-
11. Niessen, S. J. M. et al. (2023) Efficacy and safety of once daily oral sodium-glucose co-transporter-2-inhibitor velagliflozin compared to twice daily insulin injection therapy in diabetic cats. Oral abstract presentation, 2023 ECVIM-CA Forum, Barcelona, Sept 21-23.
-
12. VMD. Summary of Product Characteristics (SPC): Senvelgo® 15mg/ml oral solution for cats (velagliflozin). Veterinary Medicines Directorate, UK.
-
13. CM Research (2022) Small animal vets UK April 2022. Syndicated Sales Rep Survey.
